Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer

Nature Reviews Cancer

Volumn 10, Issue 5, 2010, Pages 371-378

  Kulasingam, Vathany ^a   Pavlou, Maria P ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CA 125 ANTIGEN; CLUSTERIN; COLLAGEN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR I; EPIDIDYMAL SECRETORY PROTEIN; FIBULIN; GALECTIN 1; IMMUNOGLOBULIN HEAVY CHAIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LIPOCORTIN 2; OSTEOPONTIN; PROTEASOME; RIBONUCLEASE; RIBONUCLEASE T2; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 4; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN;

ASCITES; BIOINFORMATICS; BIOLOGY; BLOOD SAMPLING; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CANCER TISSUE; CLINICAL TRIAL; DISEASE MARKER; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL LITERATURE; MICROARRAY ANALYSIS; NONHUMAN; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; TUMOR XENOGRAFT;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SPECTROMETRY; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951623830     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2831     Document Type: Review

References (59)

1. Jemal A., et al. Cancer statistics 2008. CA Cancer J. Clin. 58 71-96 (2008).
2. Konstantinopoulos, P. A., Spentzos, D. & Cannistra, S. A. Gene-expression profiling in epithelial ovarian cancer. Nature Clin. Pract. Oncol. 5, 577-587 (2008).
3. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
4. Diamandis, E. P., Fritsche, H. A., Lilja, H., Chan, D. W. & Schwartz, M. K. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. (AACC Press, Washington DC., 2002).
5. Kohn, E. C., Mills, G. B. & Liotta, L. Promising directions for the diagnosis and management of gynecological cancers. Int. J. Gynaecol. Obstet. 83 (Suppl. 1), 203-209 (2003).
6. Rustin, G. J., Nelstrop, A. E., Tuxen, M. K. & Lambert, H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7, 361-364 (1996).
7. Huhtinen, K., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100, 1315-1319 (2009).
8. Meinhold-Heerlein, I. et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin. Cancer Res. 13, 458-466 (2007).
9. Menon, U. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327-340 (2009).
10. Visintin, I. et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065-1072 (2008).
11. Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054-1061 (2001).
12. Ransohoff, D. F. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst. 97, 315-319 (2005).
13. Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M. & Potter, J. D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 10 0, 1432-1438 (2008).
14. Jacobs, I. J. & Menon, U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics. 3, 355-366 (2004).
15. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1, 845-867 (2002).
16. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
17. Karsan, A. et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525-1528 (2005).
18. Banks, R. E. et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51, 1637-1649 (2005).
19. Diamandis, E. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 96, 353-356 (2004).
20. Diamandis, E. P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell Proteomics 3, 367-378 (2004).
21. Simpkins, F., Czechowicz, J. A., Liotta, L. & Kohn, E. C. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 6, 647-653 (2005).
22. Su, F. et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark. Insights 2, 369-375 (2007).
23. Nossov, V. et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 199, 215-223 (2008).
24. Zhang, Z. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
25. Diamandis, E. P. Validation of breast cancer biomarkers identified by mass spectrometry. Clin. Chem. 52, 771-772 (2006).
26. Chang, H. W. et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Cancer Inst. 94, 1697-1703 (2002).
27. Stroun, M. et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46, 318-322 (1989).
28. Adam, R. A. & Adam, Y. G. Malignant ascites: past, present, and future. J. Am. Coll. Surg. 198, 999-1011 (2004).
29. Tamsma, J. T., Keizer, H. J. & Meinders, A. E. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann. Oncol. 12, 1353-1357 (2001).
30. Gortzak-Uzan, L. et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7, 339-351 (2008).
31. Kondo, T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB. Rep. 41, 626-634 (2008).
32. Good, D. M. et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res. 6, 4549-4555 (2007).
33. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84 (2002).
34. Bengtsson, S. et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J. Proteome Res. 6, 1440-1450 (2007).
35. Kulasingam, V. & Diamandis, E. P. Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer 123, 2007-2012 (2008).
36. Faca, V. M. et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE 3, e2425 (2008).
37. Kelly-Spratt, K. S., Kasarda, A. E., Igra, M. & Kemp, C. J. A mouse model repository for cancer biomarker discovery. J. Proteome Res. 7, 3613-3618 (2008).
38. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nature Rev. Cancer 7, 645-658 (2007).
39. Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966-971 (2007).
40. Pitteri, S. J. et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4, e7916 (2009).
41. Bignotti, E. et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405-416 (2006).
42. Welsh, J. B. et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. USA 100, 3410-3415 (2003).
43. Tan, D. S., Lambros, M. B., Natrajan, R. & Reis-Filho, J. S. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab. Invest. 87, 737-754 (2007).
44. Spentzos, D. et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22, 4700-4710 (2004).
45. Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 11 2, 40-46 (2009).
46. Vargo-Gogola, T. & Rosen, J. M. Modelling breast cancer: one size does not fit all. Nature Rev. Cancer 7, 659-672 (2007).
47. Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnol. 24, 971-983 (2006).
48. Kuk, C. et al. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol. Cell Proteomics 8, 661-669 (2009).
49. Gunawardana, C. G. et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteome. Res. 8, 4705-4713 (2009).
50. Kuk, C. et al. Nidogen-2: a new serum biomarker for ovarian cancer. Clin. Biochem. 43, 355-361 (2009).
51. Hellstrom, I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695-3700 (2003).
52. Moore, R. G. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108, 402-408 (2008).
53. Davidson, B. et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 100, 2139-2147 (2004).
54. He, Z. & Bateman, A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J. Mol. Med. 81, 600-612 (2003).
55. Jones, M. B., Spooner, M. & Kohn, E. C. The granulin-epithelin precursor: a putative new growth factor for ovarian cancer. Gynecol. Oncol. 88, S136-S139 (2003).
56. Jones, M. B. et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res. 9, 44-51 (2003).
57. Simpson, R. J., Bernhard, O. K., Greening, D. W. & Moritz, R. L. Proteomics-driven cancer biomarker discovery: looking to the future. Curr. Opin. Chem. Biol. 12, 72-77 (2008).
58. Diamandis, E. P., Hanash, S., Lopez, M., Carr, S. & Petricoin, E. F. Protein quantification by mass spectrometry: is it ready for prime time? Clin. Chem. 55, 1427-1430 (2009).
59. Addona, T. A. et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nature Biotechnol. 27, 633-641 (2009).